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Background: Despite effective prevention strategies and increasing investments in global health, maternal to child
transmission (MTCT) of HIV remains a significant problem globally, especially in sub-Saharan Africa. In 2012, there
were 94,000 HIV-positive pregnant women in Mozambique. Approximately 15% of these women transmitted HIV to
their newborn infants, resulting in nearly 14,000 new pediatric HIV infections that year. To address this issue, in
2013, the Mozambican Ministry of Health implemented the World Health Organization-recommended “Option B+”
strategy in which all newly diagnosed HIV-positive pregnant women are counseled to initiate combination
anti-retroviral therapy (ART) immediately upon diagnosis regardless of CD4 count and to continue treatment
for life. Given the limited experience with Option B+ in sub-Saharan Africa, few rigorous pragmatic trials have
studied this new treatment strategy.
Methods: This study utilizes an initial formative research process involving patient and health care provider
interviews and focus groups, workforce assessments, value stream mapping, and commodity utilization assessments to
understand the strengths and weaknesses in the current Option B+ care cascade. The formative research is intended to
guide identification and prioritization of key workflow modifications and the development of an enhanced adherence
and retention package. These two components are bundled into a defined intervention implemented and evaluated
across six health facilities utilizing a stepped wedge randomized controlled trial study design. The overall objective of
this trial is to develop and test a pilot intervention in central Mozambique to implement the new Option B+ guidelines
with high fidelity and increase the proportion of HIV-positive pregnant women in target antenatal clinics (ANC) who
start ART prior to delivery and are retained in care.
Discussion: This pragmatic study utilizes research strategies that have the potential to meaningfully improve the
Option B+ care cascade in central Mozambique and to decrease the MTCT of HIV. This trial is designed to identify
critical low-cost improvement strategies that can be bundled into a defined intervention. If this intervention has a
measurable impact, it can be rapidly scaled up to other ANC in Mozambique and sub-Saharan Africa.
Trial registration: ClinicalTrials.gov: NCT02371265.
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HIV remains the leading cause of death globally among
women of reproductive age [1-3]. In 2012, only 62% of
pregnant women were tested for HIV and started on
antiviral therapy [1]. An estimated 90% of the world’s 2.5
million children under 15 years old living with HIV are
in sub-Saharan Africa [4]. Over 95% of pediatric HIV
infections result from mother-to-child transmission
(MTCT) [4]. The rate of MTCT of HIV is 20%–45%,
15%–30% transmission risk in utero or at delivery, and
5%–20% risk through breastfeeding overall, reaching
30%–60% in low- and middle-income countries (LMIC)
[5,6]. Without treatment, half of all children living with
HIV die by their second birthday [2]. Short courses of
anti-retroviral (ARV) drugs started early in pregnancy or
during labor can reduce the risk of in utero and peripar-
tum HIV transmission two- to threefold [5]. In resource-
poor settings where caesarean delivery is rarely available
or safe, initial prevention of MTCT (PMTCT) efforts
focused on reducing MTCT using ARV therapy during
labor and delivery, promotion of exclusive breastfeeding
for 6 months, and then complete breastfeeding cessation
[7-10]. PMTCT includes testing and counseling, family
planning counseling, provision of an appropriate anti-
retroviral regimen for women and newborns, and sup-
port for safer infant feeding.
In Africa, a troubling pattern of loss to follow-up
(LTFU) has emerged at each stage of the PMTCT “treat-
ment cascade.” A 2004 study in South Africa showed a
loss-to-follow-up rate of 85% at 12 months by HIV-
exposed infants [11,12]. Data from Malawi in 2005
showed cumulative loss-to-follow-up rates of 55% as
early as the 36th week of pregnancy, 68% at delivery,
70% at 1st postnatal visit, and 81% at the baby’s 6-month
postnatal visit in rural district hospitals [13]. Data from
Kenya reveal high drop-out rates as well: 31.5% of HIV-
positive women do not return for their HIV test results,
53.6% of those who got their results did not enroll in an
HIV clinic, and 80.7% do not return for delivery [12].
Mozambique’s 11.1% HIV prevalence rate and under-5
mortality rate of 87 per 1,000 live births are among the
most severe in sub-Saharan Africa [1,14]. Mozambique
began the scale-up of free national HIV care services in
2004 including combination anti-retroviral triple therapy
(ART), and by 2012, an estimated 282,000 people had
started ART [1,3]. The national PMTCT program, initi-
ated in 2002 provides free HIV counseling and universal
opt-out testing for pregnant women attending antenatal
clinics (ANC) and maternities. Despite many successful
efforts such as the scale-up of ART and the use of ARVs
during labor and delivery for most HIV-positive pregnant
woman, in 2012, Mozambique still reported over 77,000
AIDS-related deaths, 120,000 new HIV-infected individ-
uals including 14,000 infants, and 1,600,000 adults andchildren living with HIV [1,3]. During 2012, there were an
estimated 94,000 HIV-positive pregnant women in
Mozambique and 79% received some form of ARV ther-
apy (approximately 65,000 got zidovudine (AZT) and
10,000 ART) [1,3]. Despite this fact, 15% of HIV-positive
pregnant women transmitted HIV to their newborn in-
fants, resulting in the majority of the 14,000 pediatric HIV
infections that year [1]. As a result, treating HIV-positive
pregnant women with combination ART and not just
AZT to prevent new pediatric HIV infections is a major
strategic priority for the Mozambique Ministry of Health
(MoH) [3].
In 2010, the World Health Organization (WHO)
developed new treatment guidelines, termed “Option B,”
that emphasized early initiation of ART in antenatal care
for all HIV-positive pregnant women [15]. According to
Option B, those with CD4 ≤ 350 cell/mm3 initiate ART
as therapy for life, while those with CD4 > 350 start ART
in ANC as prophylaxis and discontinue treatment after
cessation of breastfeeding. In 2012, the WHO issued a
programmatic update endorsing a third option termed
“Option B+” in which HIV-positive pregnant women
initiate ART during pregnancy regardless of CD4 count
and continue treatment for life [16]. In sub-Saharan
Africa, Option B+ was first piloted and then widely
implemented in Malawi [17,18].
The new Option B+ approach has been adopted by the
MoH in Mozambique and is in the adolescent phase of
implementation. As in many African settings, numerous
health system factors present major challenges to success-
ful adoption of the guidelines [18,19]. In Mozambique,
ANC and HIV testing coverage is high but there is sub-
stantial LTFU at successive stages in the treatment cas-
cade, limited counseling for women, and many barriers to
actively track those women lost to follow-up [20]. Early
MoH data suggests significant challenges remain for re-
tention in care and adherence for women started on ART
via the new Option B+ framework in Manica and Sofala
provinces and throughout Mozambique. The successful
implementation of new Option B+ WHO guidelines
therefore requires major streamlining of links among
ANC, PMTCT, and ART services to successfully reduce
the rates of pediatric HIV infection in Mozambique.
Goals and objectives
The overall objective of this study is to develop and test a
pilot intervention in central Mozambique to implement
the new WHO guidelines with high fidelity and increase
the proportion of HIV-positive pregnant women in target
ANC clinics who start ART prior to delivery and improve
retention in acre after 90 days. The intervention empha-
sizes a WHO-defined Option B+ approach; HIV-positive
mothers will be referred for ART at the time they receive a
positive HIV test result during their first ANC visit.
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Trial design
The project utilizes an initial formative research process
to understand inefficiencies in the current Option B+
care cascade, to guide identification and prioritization of
key workflow modifications and the development of an
enhanced adherence and retention package. These two
components, described in detail below, are bundled into a
defined intervention implemented and evaluated across
six health facilities utilizing a stepped wedge randomized
controlled trial (with the health facility as the unit of
randomization).
Study facilities and setting
As a facility-level intervention, the proposed “test-and-
treat” Option B+ intervention is implemented through a
stepped wedge design (described below) in six high-
volume health centers providing PMTCT and ART ser-
vices in the Mozambican national health system. These
health centers serve communities along the highly pop-
ulated Beira highway and railway transport corridor that
passes through Sofala and Manica provinces (Figure 1),
from the port city of Beira on the Indian Ocean to the
Zimbabwe border [21].Figure 1 Map of Mozambique—provinces and provincial capitals [12].Intervention sites include three health facilities in
Sofala Province (Macarungo, Munhava, and Dondo) and
three in Manica Province (Nhamaonha, 1° de Maio, and
Gondola). All of these public health facilities provide the
full range of PMTCT services, including HIV testing, ac-
cess to CD4 testing (four out of six through transport to
a central lab), and ART. ART has already been decentra-
lized to ANC through MoH trainings. The intervention
will be designed to enhance the new national MoH
Option B+ ART policy in which all pregnant women at-
tending their first ANC visit will be tested for HIV and,
if positive, will be provided with first-line triple ART
(TDF + 3TC + EFV, single daily fixed-dose combination)
during that same visit, or within 14 days of the first visit
and HIV test.
Central Mozambique
In the central provinces of Sofala and Manica where the
research is conducted, the provincial HIV prevalence
rates of adults aged 15–49 years are among the highest
in the country for women at 15.6% and 17.8%, respect-
ively, and 14.8% and 12.6% for men [22]. The prevalence
among pregnant women in 2009 was estimated at 18%
[23,24]. HIV testing and treatment services in Manica
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and financial support from Health Alliance International
(HAI), a US non-profit affiliated with the University of
Washington, School of Public Health. By early 2010,
ART had been made available in 39 public sector sites
[24]. In Manica, over 15,000 and, in Sofala, nearly 22,000
Mozambicans have started ART.
In 2010, PMTCT services were offered in routine ante-
natal care in 93 health facilities in Manica and 110 facil-
ities in Sofala. First ANC visit coverage is consistently
high at over 90% for Sofala and Manica provinces
[24,25]. HIV testing at the first ANC visit has also
attained consistently high rates of 90% in both provinces
through the current opt-out testing program [25]. How-
ever, on average, women arrive late, between 19 and
25 weeks mean gestational age (unpublished data).
Prior to the introduction of Option B+, there were a
number of documented challenges in the PMTCT care
cascade: eligible HIV-positive pregnant women were re-
ferred to adult ART services but only about 20% started
ART, only 29% of HIV-positive mothers received nevira-
pine during labor in central Mozambique, and only 60%
of births occurred at a health care facility [22-24].
Recent preliminary studies (2009–2010) conducted in
the proposed research sites by UW and HAI researchers
confirmed these previously reported barriers to care and
sources of LTFU. A recent study of ART initiation and
the PMTCT treatment cascade in seven large health
centers in Manica and Sofala, which include two of the
target sites included in this proposal (Munhava
highlighted in Figure 2 and Nhamaonha), showed
major LTFU and very small proportions of eligible
positive mothers initiating ART [20].
This observational study, led by Chris Dodd and Jennifer
Einberg, examined PMTCT LTFU under the previous
protocol. The proportion that started ART varied signifi-
cantly across the sites, but was low for each. Only about
40% of HIV-positive women actually received their CD4
results within 30 days of the first ANC visit, and only 40%
of those eligible managed to start ART. Overall, only
19.3% of eligible women started ART across all the sites
(see Figure 3). Province-wide program data from 2010
suggest similar patterns; only about 10% (8% in Manica
and 12% in Sofala) of HIV-positive pregnant women
started ART, while data suggests that an estimated 40%
were actually eligible based on the protocol for ART initi-
ation at that time [25].
Three recent qualitative studies by HAI researchers
that focus on patient experience further corroborate
sources of LTFU from the perspective of patients. Pa-
tients reported that requirement for multiple visits prior
to ART initiation created major barriers for women be-
cause of transport costs and fears of unintentional HIV
status disclosure causing stigmatization [26,27]. The laststudy revealed major gaps in understanding among HIV-
positive women about steps to follow for care, benefits of
care, and lack of system tools to support patient follow-up
to ART and through postpartum visits. Women reported
confusion about integrated ANC services, the purpose of
the various tests and treatments provided (i.e., syphilis
testing and treatment, IPT for malaria, and HIV and CD4
testing), and the need for follow-up visits [28].
Together, these studies indicate that PMTCT services
and ART referrals require excessive repeat visits, provide
insufficient information to patients, and lack patient
tracking tools to ensure follow-up. The CD4 testing
process and subsequent preparatory visits were associ-
ated with major delays and drop-offs in initiating ART
and LTFU. Based on this evidence, interventions to in-
crease earlier ART initiation and subsequent treatment
adherence will require major streamlining of the
process coupled with improved adherence counseling
[29]. The Option B+ approach provides a model to
achieve this streamlining if appropriately designed to
capitalize on the strengths and recognize the constraints
in the Mozambique heath system.
Randomization
The introduction of the intervention in the study sites
will occur in three steps following a stepped wedge
design [30]. Prior to randomization, the six sites were
stratified by province, and one site from each province
(two total) was randomly selected to initiate the inter-
vention at each of three stepped time points (months 5,
8, and 11; see Figure 4). Each step is separated by
3 months to allow an adequate number of people to be
tested and initiate ART in each site (1.5 months, i.e.,
1 month testing plus 14 days) and outcomes to be mea-
sured prior to the subsequent step (1.5 months, i.e.,
45 days post-ART initiation). The implementation process
includes staff training, integration of new adherence strat-
egies, and intensive supervision and mentorship by the
study staff and health facility managers to troubleshoot
problems that arise.
Intervention description
Step one: formative research to improve the Option
B+ protocol and model
During the first year of the project, researchers
conducted formative research at the six selected sites
to determine how to best adapt the Option B+ model
to the six facilities. The research consists of these
major activities:
1) Patient flow mapping: Researchers mapped current
patient flow patterns in the PMTCT treatment
cascade and links to ART services at each of six
target sites to identify differences and commonalities
Figure 2 Munhava health center PMTCT patient flow.
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heath center presented in Figure 2. Future state flow
maps have been created for each site to demonstrate
new flow pathways required for Option B+ in
collaboration with health center staff and managers.
Health systems data for each site, including the
monthly number of ANC visits, new ANC enrollees,
new ANC enrollees tested for HIV, CD4 tests ordered
and received, and the number of patients started on
lifelong ART were collected to identify LTFU in the
treatment cascade and ART initiation rates. These
data were gathered from ANC registries, pharmacy
registries, and ART clinic databases.
2) Workforce: Patient volume in ANC and outpatient
ART services was determined for each site during57,210
51,058
10,402
























Figure 3 Aggregate flow cascade through seven health centers in
Manica and Sofala provinces (2009).supervision visits. Staffing level, patient waiting
times, and patient flow were examined for each
site to identify workforce-related bottlenecks.
Staffing levels and training needs required to
manage new patient flows were identified for
each site and
incorporated into new patient flow mapping.
3) Flow mapping of materials and medications: Flow
and adequacy of key testing materials (HIV and CD4
testing materials), laboratory monitoring resources,
and medications required for ART and other HIV
care were examined for each health unit by assessing
pharmacy and facility records and stock-out patterns.
Current and future state flow mapping diagrams
were produced for each site to indicate proposed
medication, test materials, and patient flow changes
and projections. Investigators also flow mapped
laboratory monitoring protocols such as timing
of biochemical panels, liver function testing,
and complete blood count testing as determined
by national MoH protocols. The pilot sites
follow MoH protocol for initiating ART
and monitoring patients following ART
start.
4) Patient and health worker perspectives: Separate
qualitative focus group discussions (FGDs) were
conducted with ANC patients, health workers, and
counselors at ANC services, pharmacy, and
outpatient services at each site to a) elicit
Figure 4 Stepped wedge design of the implementation of test-and-treat intervention in PMTCT programs in central Mozambique.
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b) solicit engagement in development of new Option
B+ procedures, and c) identify key challenges to
providing treatment. Researchers will also conduct
individual interviews with facility directors and
managers to support development of new pilot
“Option B+” policies and protocols. The focus
groups were conducted by a trained interviewer
using open-ended, semi-structured interview guides,
and we will plan to have ten patients and eight health
care workers participate in FGDs or interviews at each
site. Notes were taken by a trained notetaker and
reviewed to identify themes, suggestions, and barriers
to implementation.
5) Process measures: Process measures appropriate to
all sites were defined and data collection procedures
established to measure fidelity to the core
components of the intervention as it is implemented
across the research sites. For example, measures
may include proportion of patient records properly
indicating timely counseling sessions or the first
follow-up visit adherence rates in ANC.
Step two: develop the Option B+ intervention
components: workflow modifications and an adherence
and retention package
At the end of the formative research process in
year 1, researchers developed key intervention
materials together with the district and provincial
directorates and the Beira Operations Research
Center (CIOB), part of the Mozambican MoH, and
review them for approval with health personnel at
each site. Based on formative research findings
produced in achieving the original specific aims 1
and 2, the following core components of the B+
study intervention have been designed and will be
stepped in at the study sites to improve early
retention in care and adherence:
Option B+ study core componentsI. ANC workflow modification
A. Additional SMI nurse at each site to support
clinical work but also focus on coordinating patient
follow-up and use of SMS and phone calls.
B. Workflow modification and specification at each site
to define specific tasks for each nurse to optimize
patient flow efficiency and reduce workload.
Develop and distribute corresponding job aids.
C. Additional community health workers (CHWs) at
each site as needed who can help with patient file
management, calling/texting patients, home visits,
and patient tracking.II. Adherence and retention package
A. Facilitate monthly clinical chart review:
Facility clinical director together with maternal
child health (MCH) nurses conducts meetings.
B. Adherence committee (AC):1. The committee consisting of MCH nurses and
CHWs meets weekly to review individual patient
adherence and coordinate follow-up strategies in-
cluding active follow-up and texting.
2. MCH nurses together with activistas coordinate
intensified follow-up of each mother in the first
weeks after the first initiation of ART in ANC,
using texting and home visits to encourage return
for the scheduled 7-day and subsequent visits
during the first 30-day period.
3. Following each AC meeting, the chief MCH
nurse coordinates and ensures follow-up with pa-
tients by CHWs through systematic use of: SMS texting protocol developed to define
messages and timing.
 Home visits with systematic supervision and
follow-through using supervision checklist and
AC review.
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1. Modified messaging for the first counseling
session with repeat counseling for each visit in
first 30 days (7 days, 3 weeks, and before the
first 30-day refill) and subsequent visits using
content of the counseling over the next several
months, based in part on data from formative
research period and approved by MoH.
Content includes enhanced counseling about
partner notification and testing, side effects,
and explanation of the ART/ANC process,
with dissemination of intensified counseling
messages to peer support groups.D. Supportive supervision: continuous quality
improvement approach (CQI):
1. Refresher ART and Option B+ training
provided for all staff involved.
2. The AC conducts monthly health facility
ANC/ART data review to trouble shoot and
resolve bottlenecks in patient flow.
3. Option B+ checklist provided to clinical
director at each HF to ensure quality in
registry and patient file data collection, patient
tracking processes registries properly filled out,
and patient follow-up conducted.
4. Option B+ checklist provided to MCH nurse
for supervision of CHW patient follow-up.Step three: stepped implementation of the Option B
+ intervention bundle with concurrent impact
evaluationFollowing the development of intervention compo-
nents and before intervention implementation, in each
facility as they are stepped in (designated as the “S” in
Figure 4), a total of 25 staff (ANC nurses, receptionists,
physicians, and physicians assistants or técnicos) partici-
pate in a 1-week training. The intervention bundle will
be rolled out across the six intervention sites in three
steps as described in Figure 4. The trainings focus on
the MoH Option B+ protocol and the intervention core
components as described above. Implementation train-
ings will include: a) refresher trainings on ART
provision for MCH (SMI) nurses; b) new Option B+
policies, procedures, and drug regimes; c) laboratory
testing protocols including CD4 count, hemograms,
liver function testing, and biochemical panels as out-
lined by MOH PMTCT guidelines; d) new flow charts,
job aids, treatment checklists, and data collection proce-
dures; e) patient visit schedule for ANC and ART
follow-up consultations through final postpartum visit;
f ) postpartum visit procedures for transfer and referrals of
ART patients to outpatient services; and g) supervisionprocedures by physicians or physician assistants (técnicos)
from outpatient services. Data will be collected as de-
scribed below and will be evaluated in near real time to
allow for concurrent impact evaluation.
Implementation process measures
Throughout the intervention period, research teams will
engage in process evaluation procedures to monitor the
intervention and outcomes. These will include indicators
for HIV testing, ART initiation, pharmacy refill rates,
patient follow-up through visits and texts, adherence
committee meetings, counseling sessions, and other key
intervention activities. Researchers will conduct inter-
views with health workers to troubleshoot workflow
challenges and bottlenecks and evaluate supervision
practices. The process evaluation includes the following
components:
 Weekly visits– During the first 6 weeks of intervention at each
facility: discussions with health workers (not
requiring consent) to “fine tune” and adjust the
intervention (while retaining core components). Monthly visits to health facilities– Routine health facility data for outcome indicators
collected monthly from registries and patient files.
– Discussions with health workers (not requiring
consent) to “fine tune” and adjust the intervention
(while retaining core components).
– Collect information concerning fidelity to core
components as defined above. Quarterly visits– Individual interviews (consented) with key health
staff, including activists to assess intervention
strengths and challenges.
– Focus group discussions with HIV+ mothers
(consented) who have initiated ART to assess
intervention strengths and challenges. Stepped wedge schedule– Key outcomes measured and calculated per stepped
wedge schedule collected from registries and patient
files.
Study timeline
Year 1 focused primarily on formative research. Year 2
included designing the intervention and seeking IRB and
MoH approvals, and in year 3, the intervention will be
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concurrent evaluation of impact as outlined in Figure 4.
Study measures and primary outcomes
We will measure early retention by calculating scheduled
30-day visit rates for pharmacy refill (up to 45 days from
ART initiation) among women who initiate ART under
the study intervention model and compare these rates to
women starting ART before the intervention, while
controlling for trends over time. We will also calculate
90-day adherence rates among women who initiate ART
under the study intervention model and compare these
rates to women starting ART before the intervention,
while controlling for trends over time. We hypothesize
that the proportion of women initiating ART during the
intervention phase who return for their 30-day refill visit
within 45 days will increase from 50% to at least 70%.
We also hypothesize that the proportion of women
initiating ART during the intervention phase who have
90-day ART adherence rates ≥90% based on pharmacy
refill data will increase from 40% to a least 60%.
As a secondary, but critical, outcome, we will meas-
ure, monitor, and compare the proportion of HIV-
positive pregnant women starting appropriate ART
within 14 days of HIV testing before and after the
intervention. Option B+ rollout data for ART initiation
collected during the formative research period have
varied widely among the six sites; however, MoH offi-
cials are confident that ART initiation rates will im-
prove substantially and stabilize at a higher level using
current protocols before the intervention begins, so
follow-up remains the greater challenge. The interven-
tion will seek to ensure that each site achieves at least
75% ART initiation (of mothers testing HIV-positive)
within 14 days of HIV testing, and researchers will
monitor and troubleshoot site performance throughout
the research period. Study outcomes are summarized
in Table 1.
Data sources
Research teams will measure patient ART adherence by
extracting data from routine health records. There are
three sets of patient health records system that re-
searchers will have access to for each subject: 1) theTable 1 Option B+ stepped wedge study outcomes measures
Study measure
1. First month ART pharmacy refill rates for
newly diagnosed HIV-positive pregnant women
# of newly diagnose
2. 90-day ART pharmacy refill rates for newly
diagnosed HIV-positive pregnant women
# of newly diagnosed HIV‐posit
3. The percentage of newly diagnosed HIV-positive
pregnant women that initiate ART within 14 days
# of newly diag
ART anti-retroviral therapy, HIV human immunodeficiency virus, PMTCT prevention oANC registry that is completed for every woman in her
initial ANC consultation, 2) the HIV treatment registry
and chart that is used for each patient who initiates
ART, and 3) the refill records of the pharmacy. The data
extracted from each of these sources will be consolidated
into a single Microsoft Access database. Once consoli-
dated in the new data set, the patients will be identified
using a new study-specific identification number in the
data set for analysis. Data extraction from registries is
performed by trained study team members in each facil-
ity and compared for consistency. In cases of inconsist-
ency, data collection will be repeated.
Analysis
All data will be collected in Mozambique and analyzed
using Stata SE (StataCorp, College Station, TX). We will
compare outcomes in the pre- and post-intervention
phases and will use an intention-to-treat analysis that
adjusts for clustering by health facility and changes over
time. Two analysis approaches will be considered.
First, if each measurement period has a similar num-
ber of observations per period per site, each site will
contribute four outcome measurements for 30-day ART
pharmacy refill rates over time (one for each step period
described in Figure 4), and the outcome measures (pro-
portions) will be collapsed into continuous numeric vari-
ables. We will then perform a linear regression analysis
for repeated measure panel data, specifying our outcome
as the dependent (continuous) variable and intervention
status (yes/no) as the main independent variable, while
adjusting for time and first-level autocorrelation between
successive measures. Health facility will be specified as
the panel to control for clustering by clinic.
If the number of observations does vary over time and
between sites, we will do an alternative individual-level
analysis that uses individual-level data with the outcome
coded in a bivariate format (yes/no). We will then use
logistic regression to determine the relationship between
the outcome and the intervention period (pre vs. post),
while controlling for time period and clustering by site.
The analysis will also focus on the calculation of
90-day ART adherence dichotomized into good/poor as
described above, among all patients starting ART in the
post-intervention phase. To determine if over 60% ofNumerator/denominator
# of newly diagnosed HIV‐positive pregnant women
d HIV‐positive pregnant women that refill their ART prescription within 45 days of diagnosis
# of newly diagnosed HIV‐positive pregnant women
ive pregnant women that routinely refill their ART medications during the 90 days after their diagnosis
# of newly diagnosed HIV‐positive pregnant women
nosed HIV‐positive pregnant women that initiate ART within 14 days of their diagnosis
f maternal to child transmission of HIV.
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late 95% confidence intervals using the binomial method
and determine whether this interval includes (or is
above) the goal of 60%. We will compare the proportion
of patients with good 90-day adherence in the pre- vs.
post-intervention phase, using the same stepped wedge
methodology described above.
Sample size
The power calculation for this study is based on the
primary outcome (proportion of HIV-positive pregnant
women starting ART who return within 45 days for the
first 30-day refill) and based on published calculations
for stepped wedge designs [30]. For this calculation, we
estimate that at minimum 30 new HIV-positive women
will initiate ART in each of the ANC centers for each
1-month measurement period and that the baseline
proportion of women returning within 45 days is 50%,
based on data from formative research. For a two-sided
α of 0.05 and an estimated coefficient of variation (k)
between facilities of 0.2, we would have 84.4% power to
detect an expected increase in our post-intervention
outcome of 20% (i.e., from 50% to 70%). The power
changes minimally with varying coefficients of vari-
ation (i.e., 82.0% power with k = 0.4). To maintain at
least 80% power, we would be still able to detect a
difference of 19% from the baseline 50% (i.e., to 69%).
To determine the precision of our estimate for 90-day
adherence post-intervention, we estimate that an average
of 30 new HIV-positive women who initiate ART will be
identified per ANC site for each 1-month measurement
period. As there are 12 post-intervention periods under
consideration, we estimate that 720 (30 × 12) will initiate
ART. This denominator would allow a calculation of
adherence that is within ±4% for adherence rates >50%.
Ethics
The institutional review board of the Ministry of Health
of Mozambique and the University of Washington ap-
proved this study. The trial is currently registered with
ClinicalTrials.gov #NCT02371265.
Trial status
Formative research at all six sites in central Mozambique
began in March 2013. The intervention bundle was
finalized in 2014. Implementation of the stepped wedge
randomized controlled trial is in process.
Discussion
This stepped wedge randomized controlled study is
designed as a pragmatic trial to evaluate and strengthen
the current Mozambican MoH support rollout of
Option B+ in central Mozambique and to reduce high
LTFU of HIV-positive pregnant women from PMTCTservices and ART. This trial supports the development,
implementation, and evaluation of a scalable bundled
intervention designed to increase the number of preg-
nant women that are newly diagnosed with HIV at their
first ANC visit that start ART therapy and that continue
taking their HIV medications throughout their pregnancy.
There have been limited evaluations of Option B+ efforts
in sub-Saharan Africa—the introduction of Option B+ in
Mozambique provides a unique opportunity for a rigorous
randomized controlled stepped wedge trial to evaluate
and strengthen this process.
This evaluation will help to highlight current strengths
and shortcomings in the current PMTCT care cascade
on a facility-level basis. If the bundled intervention is
successful, it can be rapidly scaled up to other ANC sites
in Mozambique and sub-Saharan Africa.
The start of Option B+ and the formative research
component of this study have generated great interest
both at participating facilities and within the Mozambican
MoH. However, there have also been several challenges
thus far including the evolving MoH PMTCT guidelines
(this trial was originally designed to evaluate Option B vs
Option B+), the high volume of patients ANC staff man-
age each day, the addition of new responsibilities for these
staff, national elections, floods, and military conflict [31].
Despite these challenges, this innovative stepped wedge
trial has the potential to significantly improve the care
provided to HIV-positive pregnant women in central
Mozambique and to reduce the likelihood that they will
transmit HIV to their newborns. The results of the forma-
tive research and the intervention evaluation are likely to
be of significant interest to local, national, and inter-
national PMTCT providers and health policy experts. If
successful, this model of formative research, intervention
development, and randomized stepped wedge intervention
evaluation can be applied across other major health ser-
vices (TB, malaria, non-communicable diseases) and may
provide a practical example for how rigorous health sys-
tems research can occur in other low-income countries.
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